Ifenprodil News After announcing yesterday AGN.c AGNPF completed dosing of the third and planned final cohort in its escalating dose Phase 1 clinical study of DMT, they announced today they will be presenting their Phase 2a Ifenprodil cough data at the 9th American Cough Conference being held June 9-10.
From what they’ve released so far AGN found that Ifenprodil, given three times daily in subjects with IPF and an associated cough, reduced geometric mean cough counts by 32.0% at 4 weeks and 39.5% at 12 weeks.
A US survey found that 5% of people (approx. 12.2 million adults) reported experiencing chronic cough in the previous 12 months = there’s clearly a huge opportunity in finding a solution to chronic cough and AGN is poised to find the solution w/ only a $2.32M MC.
https://www.algernonpharmaceuticals.com/news-media/news-releases/detail/186/algernon-pharmaceuticals-to-present-phase-2-ifenprodil